XERIS BIOPHARMA HOLDINGS, INC. (XERS) Operating Margin
- Operating margin · 12 months: Value 10.91%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 10.91% | Operating income / revenue. Period ending 2026-06-30. $36.59M ÷ $335.41M × 100 ≈ 10.91% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 36.59M USD | Operating Income (Loss) |
| Revenue | 335.41M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 34.81M USD | Research and Development Expense |
| Selling, general and administration | 208.14M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $36.59M | $335.41M | (m) | $34.81M | $208.14M | 10.91% |
| 2026-03-31 | $35.90M | $314.85M | (m) | $32.20M | $191.50M | 11.40% |
| 2025-12-31 | $24.90M | $291.85M | (m) | $31.16M | $182.37M | 8.53% |
| 2025-09-30 | $9.80M | $266.14M | (m) | $29.38M | $175.01M | 3.68% |
| 2025-06-30 | $-9.82M | $246.03M | (m) | $27.79M | $173.52M | -3.99% |
| 2025-03-31 | $-22.49M | $222.55M | (m) | $25.49M | $169.12M | -10.11% |
| 2024-12-31 | $-33.65M | $203.07M | (m) | $25.56M | $163.48M | -16.57% |
| 2024-09-30 | $-45.17M | $187.36M | (m) | $25.85M | $160.91M | -24.11% |
| 2024-06-30 | $-37.19M | $181.41M | (m) | $25.00M | $153.23M | -20.50% |
| 2024-03-31 | $-44.98M | $171.36M | (m) | $25.32M | $150.87M | -26.25% |
| 2023-12-31 | $-44.01M | $163.91M | (m) | $22.34M | $146.09M | -26.85% |
| 2023-09-30 | $-49.34M | $152.67M | (m) | $20.91M | $142.88M | -32.32% |
| 2023-06-30 | $-63.21M | $134.07M | (m) | $21.92M | $140.09M | -47.14% |
| 2023-03-31 | $-66.14M | $121.37M | (m) | $19.55M | $135.44M | -54.50% |
| 2022-12-31 | $-81.94M | $110.25M | (m) | $20.97M | $137.75M | -74.32% |
| 2022-09-30 | $-115.04M | $98.22M | (m) | $26.09M | $157.57M | -117.12% |
| 2022-06-30 | $-120.62M | $79.56M | (m) | $25.71M | $149.61M | -151.61% |
| 2022-03-31 | $-127.49M | $63.14M | (m) | $27.38M | $142.55M | -201.92% |
| 2021-12-31 | $-115.16M | $49.28M | (m) | $25.16M | $125.72M | -233.68% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-83.55M | $20.16M | (m) | $20.92M | $73.73M | -414.52% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |